相关实验视频
Updated: Jul 13, 2026

11:28
Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
低常规可可摄入量对血压和生物活性氧化的影响:一个随机对照试验
Dirk Taubert1, Renate Roesen, Clara Lehmann
1Department of Pharmacology, University Hospital of Cologne, Cologne, Germany. dirk.taubert@medizin.uni-koeln.de
JAMA
|July 5, 2007
概括
每天食用富含多的黑巧克力有效降低高血压前期或第一阶段高血压患者的血压 (BP). 这种饮食干预也增强了氧化的产生,有助于改善心血管健康.
科学领域:
- 心血管研究研究心血管研究
- 营养科学 营养科学
- 临床试验 临床试验
背景情况:
- 观察性研究将可可摄入量与心血管死亡率的降低联系起来.
- 短期高剂量可可干预措施可以改善内皮功能和血压 (BP).
- 低常规可可摄入量对BP及其机制的影响仍然不清楚.
研究的目的:
- 为了研究低剂量,富含多醇的黑巧克力对血压 (BP) 的影响.
主要方法:
- 一个随机的,受控的,研究人员盲目的试验,涉及44名未经治疗的高血压前期或1期高血压的成年人 (56-73岁).
- 参与者每天摄入6.3克黑巧克力 (30毫克多) 或无多的白巧克力,持续18周.
- 主要结局是血压的变化;次要结局包括氧化和氧化应激的血标志物.
主要成果:
- 黑巧克力摄入量显著降低了静缩血压的-2.9 mmHg和静缩血压的-1.9 mmHg (P < .001).
- 黑巧克力组的高血压患病率从86%降至68%.
- 血压降低与增加的S-尼特罗斯格卢他 (血管扩张性氧化标志物) 和血中可可的出现相关.
结论:
- 作为常规饮食的一部分,少量富含多的黑巧克力可以有效降低高于最佳血压的个体的血压 (BP).
- 这种饮食干预也改善了血管扩张性氧化的形成.
- 这些发现表明,黑巧克力在管理早期高血压方面可能发挥作用.
相关概念视频
Factors affecting Blood pressure
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

